Integral Diagnostics Ltd (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.04 billion
P/E Ratio 31.65
Dividend Yield 1.86%
Shares Outstanding 198.63 million
Earnings per share 0.162
Dividend per share 0.10
Year To Date Return 22.24%
Earnings Yield 3.16%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
31 Aug 2017 $0.0400 100.00% Final 04 Oct 2017
28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

IDX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Integral Diagnostics Ltd

Integral Diagnostics Ltd is an Australian healthcare services company. The group operates in a single business. It provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients.

IDX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 Jun 2021 $5.25 $0.14 2.74% 190,752 $5.01 $5.25 $5.01
17 Jun 2021 $5.11 $-0.02 -0.39% 73,966 $5.13 $5.14 $5.06
16 Jun 2021 $5.13 $0.00 0.00% 138,104 $5.13 $5.22 $5.11
15 Jun 2021 $5.13 $0.14 2.81% 328,521 $5.01 $5.22 $4.99
11 Jun 2021 $4.99 $-0.06 -1.19% 323,310 $5.08 $5.08 $4.95
10 Jun 2021 $5.05 $0.05 1.00% 202,157 $4.97 $5.09 $4.96
09 Jun 2021 $5.00 $0.00 0.00% 186,974 $4.99 $5.04 $4.89
08 Jun 2021 $5.00 $-0.13 -2.53% 228,681 $5.08 $5.12 $5.00
07 Jun 2021 $5.13 $-0.10 -1.91% 237,962 $5.23 $5.25 $5.09
04 Jun 2021 $5.23 $0.14 2.75% 327,663 $5.10 $5.23 $5.04
03 Jun 2021 $5.09 $0.02 0.39% 343,295 $5.10 $5.13 $5.02
02 Jun 2021 $5.07 $0.11 2.22% 400,782 $4.99 $5.11 $4.91
01 Jun 2021 $4.96 $0.03 0.61% 376,053 $4.92 $5.00 $4.87
31 May 2021 $4.93 $0.08 1.65% 201,972 $4.88 $4.97 $4.86
28 May 2021 $4.85 $0.00 0.00% 110,213 $4.90 $4.90 $4.85
27 May 2021 $4.85 $-0.05 -1.02% 593,769 $4.90 $4.91 $4.84
26 May 2021 $4.90 $0.07 1.45% 257,131 $4.86 $4.91 $4.81
25 May 2021 $4.83 $-0.02 -0.41% 145,923 $4.85 $4.86 $4.81
24 May 2021 $4.85 $0.03 0.62% 218,770 $4.82 $4.89 $4.80
21 May 2021 $4.82 $0.02 0.42% 270,210 $4.84 $4.84 $4.71
20 May 2021 $4.80 $0.10 2.13% 842,388 $4.71 $4.87 $4.71

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
06 Apr 2021 John Atkin Issued 1 $8,629
Dividend Reinvestment Plan (DRP).
06 Nov 2020 Chien Ho Sell 60 $265,500
On-market trade.
01 Oct 2020 John Atkin Issued 1 $6,217
Dividend Reinvestment Plan (DRP).
18 Sep 2020 Chien Ho Sell 30 $123,000
On-market trade.
26 Aug 2020 Raelene Murphy Buy 6 $25,620
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Jacqueline Milne Executive Director Nov 2019
Dr Milne began her medical career as a practicing Radiographer at South Coast Radiology prior to commencing her medical degree and radiology qualifications. Dr Milne's interests include women's imaging, medical training and general procedural work. She is Member of Integral Clinical Leadership Committee.
Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
Ms Murphy has over 30 years of experience in strategic, financial and operational leadership in both industry and professional advisory after beginning her career in audit. She was formerly a Partner in a accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career she has experience in operational and financial restructuring and in merger and acquisition integration across a range of public and private companies. He is Chair of Risk and Compliance Committee and Member of People Committee.
Ms Helen Kurincic Non-Executive ChairmanNon-Executive Director Dec 2014
Ms Kurincic has Executive and Board-level experience across the healthcare industry. She is currently a Non-Executive Director of Victorian Clinical Genetics Service, and is a senior advisor in the healthcare sector. Previously, Helen was the Chief Operating Officer and Director of Genesis Care. Prior to that, Helen held various Executive and Non-Executive healthcare sector roles including Non-Executive Director of DCA Group Ltd (diagnostic imaging services in Australia and the United Kingdom), Non-Executive Director of AMP Capital Investors Domain Principal Group, CEO of Benetas and Non-Executive Director of Melbourne Health and Orygen Research Centre. Helen has also been involved in healthcare government policy reform including appointments by health ministers as Chair of the Professional Programs and Services Committee for the Fourth Community Pharmacy Agreement and Member of the Minister's Implementation Taskforce and Minister's Reference Group for the Long Term Reform of Aged Care. She is Member of Risk and Compliance Committee and People Committee.
Mr John Atkin Non-Executive Director Oct 2015
Mr Atkin was appointed as Chair of Qantas Superannuation Limited, trustee of the Qantas Superannuation Fund. John is also an independent director of the Commonwealth Bank Group Super Fund trustee. John was Chief Executive Officer and Managing Director of The Trust Company Limited from 2009 to 2013 prior to its merger with Perpetual Limited. Prior to joining the Trust Company, John was the managing partner and Chief Executive Officer of Blake Dawson (now Ashurst). Before this, John was a senior mergers and acquisitions partner of Mallesons Stephen Jaques (now King & Wood Mallesons). John is Vice Chair of Outward Bound International Inc, and Chair of Hunters Hill Environment Action Group Inc. He is Chair of People Committee and Member of Risk and Compliance Committee.
Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
Dr Kadish followed this with several roles overseas including McKinsey and Company, CSC Healthcare in New York City, and Netcare where he was an Executive Director from 1997 to 2006. Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group (previously ASX-listed hospital group) and CEO of Laverty Pathology. He is Member of Integral Clinical Leadership Committee.
Dr Nazar Bokani Executive Director Apr 2021
Dr Bokani has working experience as a radiologist in the Netherlands, in the UK and in Australia. He was involved in the introduction of artificial intelligence (AI) into IDX workflows since 2019, and his participation in the establishment of IDX's teleradiology joint venture with Medica Group plc, MedX. At IDX, Dr Bokani has been the Chair of IDX's Western Australia Clinical Leadership Committee since 2017, a member of the company wide Integral Clinical Leadership Committee since 2017, and recently commenced as Chair of the IDX AI Steering Committee.
Ms Kirsty Lally Company Secretary Jul 2019
-
Anne Lockwood Chief Financial and Commercial Officer
-
Kirsty Lally Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 39,488,024 20.28%
Hsbc Custody Nominees (Australia) Limited 32,714,122 16.80%
Citicorp Nominees Pty Limited 16,430,515 8.44%
National Nominees Limited 7,429,610 3.82%
Bnp Paribas Noms Pty Ltd 5,705,929 2.93%
Peter J Ansley & St Leger M Reeves & Stephen Eichsteadt & Thomas Q St Leger Reeves 3,710,685 1.91%
Bnp Paribas Nominees Pty Ltd 3,569,400 1.83%
BNP Paribas Nominees Pty Ltd HUB24 Custodial Sery Ltd 2,942,412 1.51%
Wyndham Salter Pty Ltd 2,634,698 1.35%
Lethean Holdings Pty Ltd 2,467,230 1.27%
Firbar Ply Ltd 2,357,230 1.21%
Nittal. Holdings Pty Ltd 2,334,892 1.20%
New Imaging Pty Ltd 2,316,385 1.19%
NW3 Pty Ltd 2,164,375 1.11%
Mr Vincent Michael O'sullivan 2,132,000 1.10%
Lockwood Ridge Pty Ltd 2,034,942 1.05%
Willowbay Rise Pty Ltd 1,617,402 0.83%
JBWere (NZ) Nominees Limited 1,590,572 0.82%
Anacacia Pty Ltd 1,411,948 0.73%
Har Gao Holding Pty Ltd 1,194,723 0.61%
Danshabren Pty Ltd 1,194,723 0.61%
Ellsia Pty Ltd 1,194,723 0.61%
Larsen Ft Holdings Pty Ltd 1,194,723 0.61%
Mcsommertosh Pty Ltd 1,194,723 0.61%
Nesthaven Pty Ltd 1,194,723 0.61%
Thomas Radiology Pty Ltd 1,194,723 0.61%
Wakefield Family Holdings Pty Ltd 1,194,723 0.61%

Profile

since

Note